The AI in drug discovery market is experiencing rapid growth due to the increasing adoption of artificial intelligence technologies across pharmaceutical and biotechnology industries. AI is being leveraged to accelerate various stages of drug development, including target identification, compound screening, drug design, and clinical trial optimization.

The integration of Artificial Intelligence (AI) into drug discovery processes is revolutionizing the pharmaceutical industry. According to Fortune Business Insights, the global AI in drug discovery market was valued at USD 3.00 billion in 2022 and is projected to reach USD 7.94 billion by 2030, exhibiting a CAGR of 12.2% during the forecast period. This growth is driven by the increasing need for efficient drug development processes and the rising prevalence of chronic diseases worldwide.

Top Companies in the Market

• Microsoft (U.S.)
• Schrödinger, Inc. (U.S.)
• Cresset (U.K.)
• IBM (U.S.)
• Atomwise Inc. (U.S.)
• Insilico Medicine (U.S.)
• Exscientia (U.K.)
• BenevolentAI (U.K.)
• Aria Pharmaceuticals, Inc. (U.S.)
• Integral BioSciences (U.S.)
• Alphabet Inc. (U.S.)

Market Trends

• Machine learning (ML) and deep learning are widely used for molecular modeling and prediction.
• Natural language processing (NLP) helps in analyzing scientific literature and patents.
• The use of generative AI for de novo drug design is emerging.
• Investment and startup activity in this space is growing significantly.